Advertisement
Reduction in albuminuria with the renin inhibitor aliskiren may be too small to confer clinical benefit in patients with type 2 diabetes

No Benefit From Aliskiren-Tied Drops in Albuminuria

0
Overall albuminuria drop may be too small for cardiovascular, renal risk protection
Mobile telephone text messaging may be a promising new way to improve adherence to medications for chronic diseases

Mobile Texts May Up Adherence to Meds for Chronic Illness

0
Meta-analysis shows mobile phone text reminders double the odds of medication adherence
Taking prescription opioids doesn't improve movement or reduce disability for patients with neuropathic pain

Opioids Don’t Ease Disability in Neuropathic Pain

0
Medications aren't useful in restoring motion, researchers say

January 2016 Briefing – Pharmacy

0
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for January 2016. This roundup includes the latest...
Lipid-lowering therapy with ezetimibe plus simvastatin is associated with improved clinical outcomes

Ezetimibe/Simvastatin Ups Clinical Outcomes in IMPROVE-IT

0
Reduction in total primary end point events, driven by reductions in myocardial infarction, stroke
Pneumococcal vaccines can trigger a severe local and systemic inflammatory reaction in patients with cryopyrin-associated periodic syndromes

Severe Reaction to Pneumococcal Vaccines in Patients With CAPS

0
Severe local, inflammatory reaction triggered in those with cryopyrin-associated periodic syndromes
HIV resistance to the antiretroviral drug tenofovir (Viread) is common

High Level of Tenofovir Resistance for Those With HIV

0
Resistance affects almost two-thirds of those taking tenofovir in sub-Sahara Africa
Zepatier (elbasvir and grazoprevir) has been approved by the U.S. Food and Drug Administration to treat chronic hepatitis C virus genotypes 1 and 4 infections.

FDA Approves Zepatier for Chronic Hepatitis C

0
Medication indicated for patients with hepatitis C virus genotypes 1 and 4 infections
For patients hospitalized with acute myocardial infarction (AMI)

n-3 PUFA Tx After AMI Linked to Drop in Death, Recurrent AMI

0
Treatment linked to reduction in all-cause mortality, recurrent acute MI though 12-month follow-up
For patients with John Cunningham virus (JCV)

Tysabri Impacts Seroconversion in John Cunningham Virus

0
Over 14.8 months, natalizumab treatment linked to 15.9 percent increase of value in JCV+ patients